A new, promising scenario for targeted CRC therapy may be envisaged: administration of the anti-FZD10/5-FU/LPs here proposed, encapsulated in softgel capsules or suppositories, could provide an effective route for oral or rectal delivery, as employed for other compounds that need to reach the digestive canal, resisting gastric acids [55]. The gene discussed is FZD10; the disease is colorectal carcinoma.